The Landscape for the Consumer Seems to be Riddled with Land Mines; Increased Premiums, Questionable Practices, and More
In this week’s BioBlog we explore articles addressing sketchy practices by PBMs, the Cancer Moonshot’s impact on developing countries, premium hikes in Minnesota and ethical questions for drug companies.
After decades of classifying and paying claims for physician dispensing as “in-network,” the PBMs are playing a dangerous game with patient care in order to capture revenue in the growing specialty drug market.
Patients in the developing world are much more likely to be diagnosed at an advanced stage and die from cancer compared to patients in the United States and other wealthy countries.
“Once again, families who were told they would save $500 per year will instead see their health plans get more expensive,” said House Speaker Kurt Daudt, R-Crown, in a statement.
This article from Fierce Pharma outlines one company’s troubled past.
The drug is designated for treatment of women with advanced, mutant (inclusive of both germline and somatic BRCA mutations ) ovarian cancer.